Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 14Ovarian Neoplasms 12Triple Negative Breast Neoplasms 6Fallopian Tube Neoplasms 6Neoplasms 5Stomach Neoplasms 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Lymphoma 3Lung Neoplasms 3Colonic Neoplasms 3Breast Neoplasms, Male 3Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Melanoma 2Medulloblastoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelomonocytic, Acute 2Leukemia, Myeloid, Acute 2Hereditary Breast and Ovarian Cancer Syndrome 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Astrocytoma 2Zollinger-Ellison Syndrome 1Vipoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1Testicular Neoplasms 1Stage IV Fallopian Tube Cancer AJCC v6 and v7 1

Interventions

Cisplatin 27pembrolizumab 21Brachytherapy 16Radiotherapy 14Carboplatin 10Radiation 8Paclitaxel 8Platinum 71,2-diaminocyclohexaneplatinum II citrate 7Topotecan 6fludarabine 5atezolizumab 5Magnetic Resonance Spectroscopy 5Fluorodeoxyglucose F18 5Cyclophosphamide 5Bevacizumab 5durvalumab 4Nivolumab 4Gemcitabine 4tremelimumab 3temsirolimus 3human papillomavirus vaccine, L1 type 16, 18 3aldesleukin 3Radiotherapy, Intensity-Modulated 3Papillomavirus Vaccines 3Ipilimumab 3Interleukin-2 3Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 3Docetaxel 3Biopsy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Uterine Cervical Neoplasms × veliparib × Clear all
NCT01281852 2019-07-18

Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

National Cancer Institute (NCI)

Phase 1 Completed
37 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡